November 09, 2023
Associate Prof Jane Alsweiler | Neonatologist, Chair of the Policy committee of the Perinatal Society of Australia and New Zealand.
Posted On November 9, 2023
0


The recent Pharmac decision to not fund Palivizumab for high risk infants over 2024 winter is going to result in poor outcomes for infants, unnecessary significant increase in system pressure and worsening inequity.
The recent Pharmac decision to not fund Palivizumab for high risk infants over 2024 winter is going to result in poor outcomes for infants, unnecessary significant increase in system pressure and worsening inequity.